Table 6 Subgroup comparison between females and males aged > 45 years before and after propensity score matching.
Before matching | After matching | |||||
|---|---|---|---|---|---|---|
Female (n = 2451) | Male (n = 552) | p-value | Female (n = 515) | Male (n = 515) | p-value | |
Age (years) | 55.8 ± 7.3 (range, 46—88) | 55.9 ± 7.8 (range, 46—81) | 0.796 | 56.3 ± 7.5 (range, 46—83) | 55.8 ± 7.8 (range, 46—81) | 0.360 |
Extent of operation | 0.259 | 0.003 | ||||
Less than TT | 1829 (74.6%) | 399 (72.3%) | 401 (82.9%) | 362 (74.8%) | ||
TT and/or mRND | 622 (25.4%) | 153 (27.7%) | 83 (17.1%) | 122 (25.2%) | ||
Type of carcinoma | 0.774 | 0.035 | ||||
PTC | 2399 (97.9%) | 542 (98.2%) | 461 (95.2%) | 475 (98.1%) | ||
FTC | 43 (1.8%) | 9 (1.6%) | 18 (3.7%) | 8 (1.7%) | ||
HTC | 9 (0.4%) | 1 (0.2%) | 5 (1.0%) | 1 (0.2%) | ||
Tumor size (cm) | 1.0 ± 0.7 (range, 0.2 – 6.0) | 1.1 ± 0.9 (range, 0.2 – 5.5) | < 0.001 | 1.1 ± 0.9 (range, 0.2 – 5.0) | 1.1 ± 0.9 (range, 0.2 – 5.5) | 0.906 |
ETE | 177 (7.2%) | 25 4.5%) | 0.024 | 19 (3.9%) | 22 (4.5%) | 0.750 |
Multifocality | 1049 (42.8%) | 239 (42.3%) | 0.849 | 215 (44.4%) | 205 (42.4%) | 0.559 |
Bilaterality | 256 (10.4%) | 53 (9.6%) | 0.588 | 42 (8.7%) | 45 (9.3%) | 0.822 |
Lymphatic invasion | 483 (19.7%) | 172 (31.2%) | < 0.001 | 120 (24.8%) | 131 (27.1%) | 0.463 |
Vascular invasion | 41 (1.7%) | 25 (4.5%) | < 0.001 | 22 (4.5%) | 17 (3.5%) | 0.514 |
Perineural invasion | 54 (2.2%) | 13 (2.4%) | 0.873 | 11 (2.3%) | 11 (2.3%) | 1.000 |
BRAFV600E positive | 1611/2026 (79.5%) | 354/447 (79.2%) | 0.897 | 325/402 (80.8%) | 313/394 (79.4%) | 0.657 |
Harvested LNs | 10.1 ± 10.8 | 10.9 ± 14.6 | 0.151 | 9.9 ± 11.6 | 10.9 ± 15.1 | 0.230 |
Positive LNs | 1.3 ± 2.6 | 2.4 ± 4.2 | < 0.001 | 2.0 ± 3.4 | 2.3 ± 4.2 | 0.313 |
T stage | < 0.001 | 0.879 | ||||
T1 | 2153 (87.8%) | 470 (85.1%) | 423 (87.4%) | 418 (88.3%) | ||
T2 | 97 (4.0%) | 41 (7.4%) | 31 (6.4%) | 33 (7.8%) | ||
T3a | 24 (1.0%) | 16 (2.9%) | 11 (2.3%) | 11 (0.4%) | ||
T3b | 169 (6.9%) | 24 (4.3%) | 19 (3.9%) | 21 (3.5%) | ||
T4a | 8 (0.3%) | 1 (0.2%) | 0 (0%) | 1 (0.2%) | ||
N stage | < 0.001 | 0.909 | ||||
N0 | 1425 (58.1%) | 260 (47.1%) | 250 (51.7%) | 244 (50.4%) | ||
N1a | 951 (38.8%) | 265 (48.0%) | 210 (43.4%) | 214 (44.2%) | ||
N1b | 75 (3.1%) | 27 (4.9%) | 24 (5.0%) | 26 (5.4%) | ||
TNM stage | < 0.001 | 0.884 | ||||
Stage I | 1936 (79.0%) | 389 (70.5%) | 356 (73.6%) | 359 (74.2%) | ||
Stage II | 514 (21.0%) | 163 (29.5%) | 128 (26.4%) | 125 (25.8%) | ||
Stage III | 1 (0.0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Recurrence | 31 (1.3%) | 16 (2.9%) | 0.012 | 9 (1.9%) | 15 (3.1%) | 0.301 |
